What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
-
アブストラクト Ulipristal Acetate (UPA) is the only selective progesterone receptor modulator currently approved for medical management of myomas. Following several cases of liver toxicity during UPA treatment, new recommendations of PRAC (Pharmacovigilance Risk Assessment Committee) and EMA (European Medicines Agency) have been proposed, including a pre-therapeutic assessment of liver function and a close monitoring during treatment. Repeated courses of UPA have also been restricted to women who are defined as "non-eligible" for surgery. This article raises important questions and tries to provide clarification about the concept of 'non-eligibility' for myoma surgery. ジャーナル名 Journal of gynecology obstetrics and human reproduction 投稿日 2020/1/24 投稿者 Pourcelot, Anne-Gaelle; Capmas, Perrine; Laberge, Philippe; Fernandez, Herve 組織名 AP-HP, GHU-Sud, Hospital Bicetre, Department of Gynecology and Obstetrics, 78 rue;du General Leclerc, 94270 Le Kremlin Bicetre, France.;du General Leclerc, 94270 Le Kremlin Bicetre, France; Faculty of Medicine,;University Paris-Sud Saclay, 63 rue Gabriel Peri, 94270 Le Kremlin Bicetre,;France; INSERM, U1018, Centre of Research in Epidemiology and Population Health;(CESP), 82 rue du General Leclerc, 94270 Le Kremlin Bicetre, France.;University Laval, Department of Gynecology and Obstetrics, Quebec, Canada.;(CESP), 82 rue du General Leclerc, 94270 Le Kremlin Bicetre, France. Electronic;address: herve.fernandez@aphp.fr. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/31972353/ -
お問合わせ
検索
メルマガ登録
